HSBC has downgraded its recommendation for Danish pharmaceutical company Novo Nordisk from buy to hold. The bank has also sharply reduced its price target for the stock from 445 to 300 Danish kroner,...
HSBC Downgrades Novo Nordisk to Hold, Slashes Price Target Significantly